Recruiting

Prevention of Postoperative Complications by Negative Pressure Therapy After Complex Breast Cancer Surgery

There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction. That strategy of treatment-reconstruction has expanded increasingly since the last years. The current literature reports only 3 studies on the use of preventive negative pressure therapy in oncologic breast surgery. Moreover, all three are retrospective, case-control studies with serious limitations. The largest published series reports a reduction in the overall complication rate from 15.9%…

I'm interested View official listing
ClinicalTrials.gov IDNCT06265558
PhaseNA
Enrollment254
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Age18 Years and older
SexFEMALE
I'm interested View official listing

Conditions studied

Breast Cancer

About this study

There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction. That strategy of treatment-reconstruction has expanded increasingly since the last years. The current literature reports only 3 studies on the use of preventive negative pressure therapy in oncologic breast surgery. Moreover, all three are retrospective, case-control studies with serious limitations. The largest published series reports a reduction in the overall complication rate from 15.9% to 8.5%, and a significant reduction in several criteria: infection, scar dehiscence and necrosis. However, the study presents significant biases, with non-comparable populations in terms of comorbidities, surgical procedure performed, inclusion periods (and therefore experience in performing oncological surgery). There was also a high probability of under-assessment or postponement of post-operative complications, which is typical of published retrospective surgical studies. The published results therefore strongly encourage further investigation of negative pressure therapy in oncological breast surgery.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. Female ≥ 18 years 2. Patient with unilateral invasive or in situ breast carcinoma 3. Patient with or without neoadjuvant treatment 4. Patient presenting an indication for complex breast surgery by mastectomy with immediate breast reconstruction by implant or oncoplasty by T-shaped mammoplasty. 5. Patient presenting at least one of the following risk factors for scarring disorders: * Obesity with Body Mass Index BMI ≥ 30 and/or Cup size ≥ E * Active smoking or smoking cessation for less than one month * Diabetes * History of homolateral breast radiotherapy * Long-term corticosteroid therapy 6. Patient to have signed informed consent prior to study entry 7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 8. Patient affiliated with a health insurance plan. Exclusion Criteria: 1. Legal incapacity or limited legal capacity. Medical or psychological conditions preventing the patient from completing the study or signing the consent form. 2. Pregnant or breast-feeding patient as determined in medical records as part of standard patients care and follow-up 3. Patient under guardianship or safeguard of justice 4. Patient participating in an interventional study with the objective of wound healing 5. Any concurrent or planned surgical procedure on the contralateral breast

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-17.